Boston Therapeutics Inc. (BTHE)
| Market Cap | 3.31M |
| Revenue (ttm) | 11,462 |
| Net Income (ttm) | -2.71M |
| Shares Out | 111.13M |
| EPS (ttm) | -0.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 5 |
| Last Price | $0.0298 |
| Previous Close | $0.0300 |
| Change ($) | -0.0002 |
| Change (%) | -0.67% |
| Day's Open | 0.0387 |
| Day's Range | 0.0298 - 0.0387 |
| Day's Volume | 25,499 |
| 52-Week Range | 0.0055 - 0.06 |
News
There are no news available yet.
About BTHE
Boston Therapeutics, a pre-clinical and clinical-stage pharmaceutical development company, focuses on the development, manufacture, and commercialization of carbohydrate-based therapeutic drugs and dietary supplements in the United States. Its lead pharmaceutical drug candidates are BTI-320, a non-systemic carbohydrate-based compound that is in Phase IIb clinical trial to reduce post-meal elevation of blood glucose levels in Type 2 diabetic and pre diabetic patients; BTI-410, a peptide injectable compound that has completed Phase Ib clinical tr... [Read more...]
| Industry Biotechnology | Founded 2009 |
| CEO Chi-Heng Cheng | |
| Stock Exchange OTCMKTS | Ticker Symbol BTHE |
Financial Performance
In 2019, BTHE's revenue was $16,329, a decrease of -48.53% compared to the previous year's $31,723. Losses were -$3.69 million, 2.58% more than in 2018.